Xuebijing and somatostatin against acute pancreatitis: A systematic review and network pharmacology

Ji-Ping Cao,Xiang-Hua Piao,Long-Xun Zhu,Pan-Feng Feng
DOI: https://doi.org/10.1097/md.0000000000040964
IF: 1.6
2024-12-18
Medicine
Abstract:Acute pancreatitis (AP), a rapidly progressing disease characterized by severe complications and high mortality leads to many admissions to intensive care units. [ 1 , 2 ] In the last 20 years, the incidence of the disease has increased by more than 20%. [ 3 , 4 ] According to the revised Atlanta Classification, AP severity can be divided into 3 groups: mild, moderately severe, and severe. [ 5 ] AP is a common pancreatic disease, and is the result of a combination of several factors. [ 6 ] The incidence of AP is high, and the pathogenesis is more complicated. Single treatment often has poor results. After the disease progresses to severe necrotizing pancreatitis, the mortality rate increases significantly, with a case fatality rate as high as 35%. [ 7 ] For AP, the current clinical treatment measures are mainly to reduce trypsin activity, improve immune defense function, reduce the production of inflammatory factors, and avoid vascular endothelial cell damage. Somatostatin is a commonly used treatment drug for patients with AP, which can reduce the digestion of the pancreas and inhibit the secretion of pancreatic enzymes, but the long-term effect is not good, and it is difficult to achieve the expected therapeutic effect. [ 8 ]
medicine, general & internal
What problem does this paper attempt to address?